Literature DB >> 17296651

Comparison of outcomes for low-risk outpatients and inpatients with pneumonia: A propensity-adjusted analysis.

Jose Labarere1, Roslyn A Stone, D Scott Obrosky, Donald M Yealy, Thomas P Meehan, Jonathan M Fine, Louis G Graff, Michael J Fine.   

Abstract

BACKGROUND: Low-risk patients with community-acquired pneumonia are often hospitalized despite guideline recommendations for outpatient treatment.
METHODS: Using data from a randomized trial conducted in 32 emergency departments, we performed a propensity-adjusted analysis to compare 30-day mortality rates, time to the return to work and to usual activities, and patient satisfaction with care between 944 outpatients and 549 inpatients in pneumonia severity index risk classes I to III who did not have evidence of arterial oxygen desaturation, or medical or psychosocial contraindications to outpatient treatment.
RESULTS: After adjusting for quintile of propensity score for outpatient treatment, which eliminated all significant differences for baseline characteristics, outpatients were more likely to return to work (odds ratio [OR], 2.0; 95% confidence interval [CI], 1.5 to 2.6) or, for nonworkers, to usual activities (OR, 1.4; 95% CI, 1.1 to 1.8) than were inpatients. Satisfaction with the site-of-treatment decision (OR, 1.1; 95% CI, 0.7 to 1.8), with emergency department care (OR, 1.4; 95% CI, 0.9 to 1.9), and with overall medical care (OR, 1.1; 95% CI, 0.8 to 1.6) was not different between outpatients and inpatients. The overall mortality rate was higher for inpatients than outpatients (2.6% vs 0.1%, respectively; p < 0.01); the mortality rate was not different among the 242 outpatients and 242 inpatients matched by their propensity score (0.4% vs 0.8%, respectively; p = 0.99).
CONCLUSIONS: After adjusting for the propensity of site of treatment, outpatient treatment was associated with a more rapid return to usual activities and to work, and with no increased risk of mortality. The higher observed mortality rate among all low-risk inpatients suggests that physician judgment is an important complement to objective risk stratification in the site-of-treatment decision for patients with pneumonia.

Entities:  

Mesh:

Year:  2007        PMID: 17296651     DOI: 10.1378/chest.06-1393

Source DB:  PubMed          Journal:  Chest        ISSN: 0012-3692            Impact factor:   9.410


  21 in total

1.  Changes in short- and long-term cardiovascular risk of incident diabetes and incident myocardial infarction--a nationwide study.

Authors:  M L Norgaard; S S Andersen; T K Schramm; F Folke; C H Jørgensen; M L Hansen; C Andersson; D M Bretler; A Vaag; L Køber; C Torp-Pedersen; G H Gislason
Journal:  Diabetologia       Date:  2010-05-09       Impact factor: 10.122

2.  Healthcare reconsultation in working-age adults following hospitalisation for community-acquired pneumonia.

Authors:  Priya Daniel; Thomas Bewick; Tricia M McKeever; Mark Roberts; Deborah Ashton; Daniel Smith; Lenny Latip; Wei Shen Lim
Journal:  Clin Med (Lond)       Date:  2018-02       Impact factor: 2.659

3.  Community-acquired pneumonia: symptoms and burden of illness at diagnosis among US adults aged 50 years and older.

Authors:  Kathleen W Wyrwich; Holly Yu; Reiko Sato; David Strutton; John H Powers
Journal:  Patient       Date:  2013       Impact factor: 3.883

4.  Accuracy of C-reactive protein, procalcitonin, and mid-regional pro-atrial natriuretic peptide to guide site of care of community-acquired pneumonia.

Authors:  Yann-Erick Claessens; Thierry Mathevon; Gérald Kierzek; Sophie Grabar; David Jegou; Eric Batard; Clarisse Loyer; Alain Davido; Pierre Hausfater; Hélène Robert; Leila Lavagna-Perez; Bruno Bernot; Patrick Plaisance; Christophe Leroy; Bertrand Renaud
Journal:  Intensive Care Med       Date:  2010-03-16       Impact factor: 17.440

5.  Utility of two biomarkers for directing care among patients with non-severe community-acquired pneumonia.

Authors:  P P España; A Capelastegui; A Bilbao; R Diez; F Izquierdo; M J Lopez de Goicoetxea; J Gamazo; F Medel; J Salgado; I Gorostiaga; J M Quintana
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2012-08-05       Impact factor: 3.267

6.  Hospital admission decision for patients with community-acquired pneumonia: variability among physicians in an emergency department.

Authors:  Nathan C Dean; Jason P Jones; Dominik Aronsky; Samuel Brown; Caroline G Vines; Barbara E Jones; Todd Allen
Journal:  Ann Emerg Med       Date:  2011-09-09       Impact factor: 5.721

7.  Implementation of Real-Time Electronic Clinical Decision Support for Emergency Department Patients with Pneumonia Across a Healthcare System.

Authors:  Nathan C Dean; Caroline G Vines; Jenna Rubin; Dave S Collingridge; Mark Mankivsky; Raj Srivastava; Barbara E Jones; Kathryn G Kuttler; Missy Walker; Nathan Jenson; Brandon J Webb; Todd L Allen; Peter J Haug
Journal:  AMIA Annu Symp Proc       Date:  2020-03-04

8.  Discordance of physician clinical judgment vs. pneumonia severity index (PSI) score to admit patients with low risk community-acquired pneumonia: a prospective multicenter study.

Authors:  Pedro J Marcos; Marcos I Restrepo; Francisco J González-Barcala; Nilam J Soni; Iria Vidal; Pilar Sanjuàn; Diego Llinares; Lucía Ferreira-Gonzalez; Carlos Rábade; Isabel Otero-González; Pedro Marcos; Héctor Verea-Hernando
Journal:  J Thorac Dis       Date:  2017-06       Impact factor: 2.895

9.  Hispanics/Latinos With Type 2 Diabetes Have Functional and Symptomatic Pulmonary Impairment Mirroring Kidney Microangiopathy: Findings From the Hispanic Community Health Study/Study of Latinos (HCHS/SOL).

Authors:  Oana L Klein; Larissa Aviles-Santa; Jianwen Cai; Harold R Collard; Alka M Kanaya; Robert C Kaplan; Gregory L Kinney; Eliana Mendes; Lewis Smith; Gregory Talavera; Donghong Wu; Martha Daviglus
Journal:  Diabetes Care       Date:  2016-09-09       Impact factor: 19.112

10.  The value of prognostic indices for pneumonia.

Authors:  Jennie Johnstone; Sumit R Majumdar; Thomas J Marrie
Journal:  Curr Infect Dis Rep       Date:  2008-05       Impact factor: 3.725

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.